Agenus Current Ratio 2010-2022 | AGEN

Agenus current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Agenus Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.25B $0.17B 1.45
2022-06-30 $0.29B $0.16B 1.81
2022-03-31 $0.29B $0.16B 1.78
2021-12-31 $0.33B $0.16B 2.12
2021-09-30 $0.31B $0.15B 2.05
2021-06-30 $0.09B $0.17B 0.55
2021-03-31 $0.14B $0.14B 0.98
2020-12-31 $0.11B $0.13B 0.88
2020-09-30 $0.13B $0.15B 0.85
2020-06-30 $0.11B $0.14B 0.74
2020-03-31 $0.10B $0.13B 0.81
2019-12-31 $0.09B $0.12B 0.71
2019-09-30 $0.11B $0.13B 0.81
2019-06-30 $0.14B $0.12B 1.14
2019-03-31 $0.18B $0.11B 1.70
2018-12-31 $0.08B $0.07B 1.10
2018-09-30 $0.07B $0.06B 1.16
2018-06-30 $0.07B $0.05B 1.32
2018-03-31 $0.07B $0.03B 2.16
2017-12-31 $0.07B $0.06B 1.30
2017-09-30 $0.08B $0.05B 1.55
2017-06-30 $0.11B $0.03B 3.36
2017-03-31 $0.14B $0.04B 3.80
2016-12-31 $0.09B $0.04B 2.24
2016-09-30 $0.11B $0.04B 3.14
2016-06-30 $0.14B $0.03B 4.12
2016-03-31 $0.16B $0.03B 5.17
2015-12-31 $0.18B $0.03B 6.36
2015-09-30 $0.21B $0.03B 7.39
2015-06-30 $0.15B $0.03B 5.78
2015-03-31 $0.09B $0.02B 4.06
2014-12-31 $0.04B $0.01B 4.62
2014-09-30 $0.06B $0.02B 3.54
2014-06-30 $0.07B $0.02B 3.61
2014-03-31 $0.08B $0.01B 5.24
2013-12-31 $0.03B $0.01B 2.74
2013-09-30 $0.03B $0.01B 3.20
2013-06-30 $0.01B $0.01B 2.01
2013-03-31 $0.02B $0.01B 3.18
2012-12-31 $0.02B $0.01B 4.70
2012-09-30 $0.03B $0.01B 5.34
2012-06-30 $0.03B $0.01B 5.77
2012-03-31 $0.03B $0.01B 4.71
2011-12-31 $0.01B $0.01B 2.53
2011-09-30 $0.02B $0.01B 2.73
2011-06-30 $0.01B $0.01B 2.77
2011-03-31 $0.02B $0.01B 3.03
2010-12-31 $0.02B $0.01B 3.85
2010-09-30 $0.03B $0.04B 0.64
2010-06-30 $0.03B $0.01B 6.25
2010-03-31 $0.03B $0.01B 4.57
2009-12-31 $0.03B $0.01B 5.89
2009-09-30 $0.04B $0.01B 5.81
2009-06-30 $0.02B $0.01B 3.51
2009-03-31 $0.03B $0.01B 4.36
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.783B $0.296B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00